Larimar Therapeutics (LRMR) Non-Current Assets (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Non-Current Assets for 14 consecutive years, with $4.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 4.47% year-over-year to $4.6 million; the trailing twelve-month figure through Jun 2026 stood at $17.0 million (down 14.13% YoY), and the FY2025 full-year result was $3.8 million, down 22.37% from the prior year.
• Non-Current Assets advanced to $4.6 million in Q2 2026 per LRMR's latest filing, from $3.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $17.3 million in Q1 2024 and bottomed at $3.8 million in Q4 2025.
• Historically, Non-Current Assets has averaged $6.0 million across 5 years, with a median of $5.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 216.96% in 2024, then slumped 72.81% in 2025.
• Over 5 years, Non-Current Assets stood at $5.7 million in 2022, then gained by 1.66% to $5.8 million in 2023, then decreased by 14.57% to $4.9 million in 2024, then fell by 22.37% to $3.8 million in 2025, then grew by 21.2% to $4.6 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $4.6 million, $3.8 million, and $4.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.